Podcasts about Gadolinium

In this raw and deeply personal episode of Everyday Epigenetics: Raw. Real. Relatable., Susan opens up about her terrifying journey with Gadolinium Deposition Disease (GDD), a condition triggered by contrast injections commonly used in MRIs. What started as a routine scan for hip pain spiraled into months of excruciating suffering, disbelief from doctors, and a desperate search for answers.Susan is joined by Dr. Richard Semelka, one of the world's leading experts on MRI safety and the physician who has dedicated his career to researching, identifying, and treating GDD. Together, they shine light on a condition too often dismissed, ignored, or misdiagnosed, and discuss why awareness could be life-saving for countless people undergoing MRIs with contrast.This conversation is equal parts personal testimony, medical expertise, and call to advocacy. If you or someone you love has ever had, or may need, a contrast MRI, this is an episode you cannot afford to miss.In this episode:Susan's unfiltered story of surviving GDD and finding validation after years of pain and dismissalWhat Gadolinium Deposition Disease actually is, its symptoms, and why it's often overlookedWho is most at risk, and why some people may react while others don'tThe latest research on heavy metal toxicities and how GDD is treatedThe critical role lifestyle and immune system regulation play in recoveryWhy informed choice matters when doctors recommend contrast MRIsThis episode is not only about awareness, it's about reclaiming your voice, listening to your body, and refusing to be silenced when you know something is wrong.Learn more about our guest Dr. Richard SemelkaDr Semelka's career is shown to be the #10 in MRI, # 12 in Medical Imaging worldwide by Scholar GPS. He has written 6 editions of textbooks on MRI of the abdomen and pelvis, 5 editions of a textbook on MR physics,  a textbook on quality improvement in Radiology and over 380 peer-reviewed articles, including the broadest range of subjects on safety issues in Radiology. Most recently he has described the entity Gadolinium Deposition Disease, on which he has written more than 16 articles. He has lectured around the world on topics in Radiology over a 35 year career. Presently he devotes his medical career to treating individuals with Gadolinium Deposition Disease and other metal toxicities. He is the president of the nonprofit GadTTRAC, an organization devoted to helping sufferers with Gadolinium and other heavy metal toxicity.RESOURCES:Connect with Dr Richard Semelka:Website: gadttrac.orgWebsite: www.richardsemelka.comFind all of Kate and Susan's Resources and links in the show notes: https://healthyawakening.co/2025/0915/episode74Connect with Susan: https://healthyawakening.co/Connect with Kate: https://theradiantlifeproject.com/Visit the website: healthyawakening.co/podcastFind listening links here: https://healthyawakening.co/linksP.S. Want reminders about episodes? Sign up for our newsletter, you can find the link on our podcast page! https://healthyawakening.co/podcast

Precision matters in cardiology. Master late gadolinium enhancement techniques to accurately assess myocardial viability and guide treatment. Credit available for this activity expires: 9/10/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/precision-imaging-cardiac-mri-late-gadolinium-enhanced-2025a1000nh4?ecd=bdc_podcast_libsyn_mscpedu

American Resources Corp CEO Mark Jensen joined Steve Darling to unveil a major step in reshoring critical materials: the launch of a fully integrated urban mining-to-magnet rare earth supply chain through the company's subsidiary, ReElement Technologies. ReElement will offer toll processing services to recycle and refine rare earth magnets into high-purity oxides—including Neodymium (Nd), Neodymium-Praseodymium (NdPr), Dysprosium (Dy), and Terbium (Tb)—at purities exceeding 99.5%, and at an average cost of just $25 to $35 per kilogram. In addition to rare earths, ReElement is actively recycling strategic and esoteric critical minerals such as Gallium, Germanium, Cobalt, Samarium, Yttrium, and Gadolinium, many of which face Chinese export restrictions. The company achieves purities up to 99.999% and often returns materials at or below Chinese market pricing—making it a strategic alternative for commercial and defense applications. Notably, ReElement is feedstock-agnostic and has already processed magnets from a wide variety of sources, including, wind turbines, automotive and power tool rotors, hard disk drives and Magnetic separators and waste. Looking ahead, Jensen revealed that ReElement is set to expand tolling partnerships to include SEG, SEG+, MREC, MREO, and other ore-based feedstocks, alongside its current antimony refining operations. This development represents a critical leap toward rare earth independence for the U.S., offering a scalable, sustainable, and secure domestic supply chain for strategic materials that power everything from clean energy to national defense. #proactiveinvestors #americanresourcescorporation #nasdaq #arec #SustainableMining, #MineralRefining, #RecyclingInnovation, #CriticalMinerals, #RareEarthRecycling, #EVRecycling, #BatteryRecycling, #GreenTechnology, #EcoFriendlySolutions, #RenewableEnergy, #ElectricVehicles, #CleanEnergy, #ResourceRecovery, #CircularEconomy, ReElementTechnologies #RareEarthElements #CriticalMinerals #SupplyChain #USManufacturing #MagnetSupplyChain #Gallium #Terbium #CleanTech #DefenseIndustry #LithiumExtraction #MiningInnovation

It's Prostate Week in Podcastistan: what happens when an MRI scan for prostatitis includes the injection of rare earth metals—should you, or shouldn't you? Gadolinium crosses the blood-brain barrier if the barrier is not fully intact—does that affect your decision? Then: a letter from an MD-PhD student at Harvard prompts musings on the federal funding of science, what science is for, how complicit universities and many scientists have been for years, and what to do. Also: uterine transplants for “trans women.”*****Our sponsors:Timeline: Accelerate the clearing of damaged mitochondria to improve strength and endurance: Go to http://www.timeline.com/darkhorse and use code darkhorse for 10% off your first order.Caraway: Non-toxic & beautiful cookware. Save $150 on a cookware set over buying individual pieces, and get 10% off your order at http://Carawayhome.com/DarkHorse10.ARMRA Colostrum is an ancient bioactive whole food that can strengthen your immune system. Go to http://www.tryarmra.com/DARKHORSE to get 15% off your first order.*****Join us on Locals! Get access to our Discord server, exclusive live streams, live chats for all streams, and early access to many podcasts: https://darkhorse.locals.comHeather's newsletter, Natural Selections (subscribe to get free weekly essays in your inbox): https://naturalselections.substack.comOur book, A Hunter-Gatherer's Guide to the 21st Century, is available everywhere books are sold, including from Amazon: https://amzn.to/3AGANGg (commission earned)Check out our store! Epic tabby, digital book burning, saddle up the dire wolves, and more: https://darkhorsestore.org*****Mentioned in this episode:Gadolinium Contrast Dye: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-gadolinium-based-contrast-agents-gbcas-are-retained-bodyLetter from Harvard: https://naturalselections.substack.com/p/letter-from-harvard/commentsHigher Education Research & Development Survey: https://ncses.nsf.gov/surveys/higher-education-research-development/2023#dataJones et al 2018. Uterine transplantation in transgender women. Bjog 126(2): 152-156: https://pmc.ncbi.nlm.nih.gov/articles/PMC6492192/pdf/BJO-126-152.pdfSupport the show

Gadolinium contrast agents used in MRIs can cause severe toxicity in 1 out of 10,000 people, leaving patients with debilitating symptoms often misdiagnosed as other conditions. Dr. Richard Semelka, a world-renowned expert in MRI safety and gadolinium toxicity, exposes the alarming reality behind gadolinium deposition disease (GDD). This condition has left countless patients struggling with brain fog, burning skin pain, stabbing bone pain, muscle spasms, and chronic fatigue—often without answers from their doctors. In today's episode, Dr. Semelka explains how gadolinium toxicity happens, the warning signs to watch for, and the treatment protocols that work. He shares why traditional medicine is so slow to recognize this condition, the shocking prevalence of misdiagnoses, and how you can protect yourself from unnecessary gadolinium exposure.  Plus, learn how chelation therapy with DTPA can help remove this toxic metal and why certain supplements and lifestyle changes can support your body's recovery.   "There are people with gadolinium toxicity who have been admitted to mental health facilities as inpatients. ~ Dr. Richard Semelka   In This Episode: - Dr. Semelka's background and experience with GDD - How gadolinium enters the body and MRI concerns - Alternatives to gadolinium contrast scans - Key symptoms of gadolinium deposition disease - Who's most vulnerable to gadolinium toxicity - Treatment options and chelation therapy - Why chelation requires multiple sessions - Managing side effects of chelation - Anti-inflammatory supplements that help - Commonly misdiagnosed conditions - Patient stories and success with treatment For more information, visit https://www.myersdetox.com    Ready to detox heavy metals? Take the quiz: http://www.heavymetalsquiz.com    Resources Mentioned: Purity Woods Age-Defying Dream Cream: Get 27% off with code WENDY at: https://puritywoods.com/wendy  Puori PW1 Whey Protein: Get 20% off with code WENDY at: https://puori.com/wendy    About Dr. Richard Semelka: Dr. Richard Semelka is a world-renowned expert in MRI safety and medical imaging. As the leading authority on gadolinium toxicity, he ranks in the top 0.05% of scholars worldwide in his field (ranked #10 in MRI and #14 in medical imaging by Scholar GPS). Dr. Semelka treats patients with gadolinium toxicity from around the world and has pioneered effective chelation protocols. His work at gadtrack.org has helped thousands understand and address gadolinium deposition disease. Learn more at https://gadttrac.org or contact Dr. Semelka at https://www.richardsemelka.com/   Disclaimer The Myers Detox Podcast was created and hosted by Dr. Wendy Myers. This podcast is for information purposes only. Statements and views expressed on this podcast are not medical advice. This podcast, including Wendy Myers and the producers, disclaims responsibility for any possible adverse effects from using the information contained herein. The opinions of guests are their own, and this podcast does not endorse or accept responsibility for statements made by guests. This podcast does not make any representations or warranties about guests' qualifications or credibility. Individuals on this podcast may have a direct or indirect financial interest in products or services referred to herein. If you think you have a medical problem, consult a licensed physician.

Full article: Use of Photon-Counting Detector CT to Visualize Liver-Specific Gadolinium-Based Contrast Agents: A Phantom Study Aishwariya Vegunta, MD, discusses the AJR article by Rau et al. exploring the potential of photon-counting detector CT, combined with low-keV virtual monoenergetic reconstructions, to visualized a hepatocyte-specific gadolinium-based contrast agent.

Voyageur Pharmaceuticals CEO Brent Willis joined Steve Darling from Proactive to announce the company has received a $600,000 grant from Alberta Innovates, a provincial Crown corporation and Alberta's largest research and innovation organization. The grant, awarded through the AICE-Market Access Program, is aimed at supporting the commercialization and market access of emerging health technologies in Alberta. Willis shared that the funds will be used for a pivotal study assessing the efficacy of Voyageur's Frances Creek barium sulfate compared to competing products. The study will focus on evaluating the performance of natural barite from Frances Creek against synthetic barium precipitate and oral iodine products. Currently, synthetic barium and diluted iodine contrast media dominate the fluoroscopy and Computed Tomography examination markets. Voyageur aims to highlight the superior imaging quality of its natural barium sulfate, attributed to its wider particle distribution. This research is expected to enhance the financial viability of the Frances Creek project and strengthen marketing strategies to drive sales growth. Willis also noted that Voyageur is in the testing and refinement phase for its five Health Canada licensed barium contrast products. The company is making steady progress toward its market launch, with a go-to-market plan that includes third-party barium sulfate imports and contract manufacturing partnerships. #proactiveinvestors #voyageurpharmaceuticalsltd #tsxv #vm #vyyrf #ctscan #xray #BrentWillis, #RainCage, #Nanoscience, #MRI, #CTScan, #MedicalBreakthrough, #Fullerenes, #Vanadium, #Gadolinium, #Bismuth, #Iodine, #Radiology, #MedicalInnovation, #DrugDevelopment, #Healthcare, #ScientificBreakthrough

Nurses Out Loud with Jodi O'Malley MSN, RN – Gadolinium, a heavy metal used in MRI contrast, can pose hidden risks like neurological and autoimmune issues. Exploring chelation therapy, immune support, and holistic care can help affected patients. Nurses must advocate for comprehensive health solutions while balancing faith, purpose, and compassion to transform care and address the broader impacts of chronic illness.

Nurses Out Loud with Jodi O'Malley MSN, RN – Gadolinium, a heavy metal used in MRI contrast, can pose hidden risks like neurological and autoimmune issues. Exploring chelation therapy, immune support, and holistic care can help affected patients. Nurses must advocate for comprehensive health solutions while balancing faith, purpose, and compassion to transform care and address the broader impacts of chronic illness.

Voyageur Pharmaceuticals CEO Brent Willis joined Steve Darling from Proactive to share details from a recently released Letter from the CEO, highlighting the company's significant achievements in 2024 and its ambitious plans for 2025. Willis reflected on 2024 as a transformative year for Voyageur, with the company entering into a Letter of Intent with a large multinational pharmaceutical company. This collaboration aims to improve production efficiencies and expand Voyageur's presence in the contrast media market. Both parties are actively working toward a definitive agreement, expected in early 2025. Voyageur introduced five new Health Canada-licensed barium contrast products aimed at raising the bar for medical imaging standards and enhancing diagnostic precision for healthcare professionals. This accomplishment followed 18 months of dedicated research and development. The company secured a $2.7 million sales distribution contract for its SmoothX 2% Barium Contrast product, solidifying its market presence in Latin America. Regulatory approvals are in progress, with sales slated to commence in the second half of 2025. Additionally, Voyageur is engaging with global distributors to broaden its reach. Voyageur is entering 2025 with a clear roadmap for advancing its product pipeline and market position, which includes extensive testing of its barium contrast formulations in human subjects is set to begin, with a focus on ensuring safety and efficacy in clinical settings. Voyageur aims to secure FDA approvals for its barium contrast products, demonstrating compliance with rigorous U.S. regulatory standards. A major initiative for 2025 involves advancing its iodine contrast drug development in the U.S. The goal is to produce the lowest-cost iodine contrast drugs in the market. Preliminary bench-scale testing has already commenced, and the company is laying the groundwork for full-scale production. With North America currently relying 100% on imported radiology drugs, Voyageur is focused on addressing critical mineral supply constraints. The company is working to establish the first secure, vertically integrated supply chain for radiology drugs in North America, aiming to fill critical gaps in the industry. As Willis explained, these efforts underscore Voyageur's commitment to innovation and its vision to redefine the radiology drug industry by providing secure, cost-effective, and high-quality solutions for healthcare professionals. With its robust pipeline and strategic partnerships, Voyageur is well-positioned for sustained growth and success in 2025 and beyond. #proactiveinvestors #voyageurpharmaceuticalsltd #tsxv #vm #vyyrf #ctscan #xray #BrentWillis, #RainCage, #Nanoscience, #MRI, #CTScan, #MedicalBreakthrough, #Fullerenes, #Vanadium, #Gadolinium, #Bismuth, #Iodine, #Radiology, #MedicalInnovation, #DrugDevelopment, #Healthcare, #ScientificBreakthrough,

Voyageur Pharmaceuticals CEO Brent Willis joined Steve Darling from Proactive to announce the commencement of human testing for the company's latest suite of barium contrast products, designed to optimize radiographic examinations of the gastrointestinal tract. The product lineup, including SmoothX, SmoothHD, SmoothLD, VisionHD, and VisionLD, is tailored to provide enhanced clarity, detail, and versatility for both adult and pediatric imaging applications. Willis emphasized the importance of this milestone, as it represents a critical step toward the company's goal of entering the Canadian market in 2025. The human testing process is being conducted in two phase with Phase 1 in Q1 2025 and will focus on assessing product performance based on key indicators such as imaging quality, diagnostic yield, contrast administration success rates, detection sensitivity, and patient safety. The company says some additional metrics will include patient satisfaction, procedure completion rates, adverse event rates, and compliance rates will also be closely monitored. These advanced formulations are designed to meet diverse clinical needs, ensuring high performance while maintaining safety and ease of use for patients. Voyageur aims to set a new standard in barium contrast agents, offering both precision and reliability in diagnostic imaging. This testing phase is an essential step in achieving regulatory approval and market readiness. #proactiveinvestors #voyageurpharmaceuticalsltd #tsxv #vm #vyyrf #ctscan #xray #BrentWillis, #RainCage, #Nanoscience, #MRI, #CTScan, #MedicalBreakthrough, #Fullerenes, #Vanadium, #Gadolinium, #Bismuth, #Iodine, #Radiology, #MedicalInnovation, #DrugDevelopment, #Healthcare, #ScientificBreakthrough,

Voyageur Pharmaceuticals CEO Brent Willis joined Steve Darling from Proactive to announce a significant milestone for the company: entering into a Letter of Intent (LOI) with a major multinational pharmaceutical company. This strategic collaboration is aimed at enhancing production efficiencies and expanding Voyageur's project portfolio within the contrast media industry. Willis explained that the proposed partnership is expected to accelerate Voyageur's development of vertically integrated production for its suite of contrast media products. The collaboration would also enable the company to expedite its entry into new segments of the contrast media market, positioning Voyageur for faster progress across its operations. The LOI serves as a precursor to a formal definitive agreement anticipated in the New Year. The agreement will define the full scope of the partnership, including the deal structure, project expectations, and timelines for achieving key milestones. Willis emphasized the importance of this collaboration, noting its potential to diversify Voyageur's product mix and drive forward the company's vision for growth in the pharmaceutical sector. This partnership marks a pivotal step in Voyageur's journey toward becoming a leading player in the contrast media industry. #proactiveinvestors #voyageurpharmaceuticalsltd #tsxv #vm #vyyrf #ctscan #xray #BrentWillis, #RainCage, #Nanoscience, #MRI, #CTScan, #MedicalBreakthrough, #Fullerenes, #Vanadium, #Gadolinium, #Bismuth, #Iodine, #Radiology, #MedicalInnovation, #DrugDevelopment, #Healthcare, #ScientificBreakthrough, #VoyageurPharmaceuticals #MedicalImaging #BrentWillis #FDAApproval #ContrastMedia #HealthCanada #PharmaceuticalInnovation #2025Milestones #DiagnosticsMarket #ProactiveInvestors

Pr. Douraied BEN SALEM est neuroradiologue au CHU de Brest, professeur des universités et chercheur au LATIM. Depuis 2012, il combine pratique clinique, recherche et responsabilité éditoriale, notamment en tant qu'éditeur en chef du « journal of neuroradiology ». Pionnier dans le domaine du recyclage du gadolinium à travers le projet MeGadoRe, il œuvre pour une radiologie plus verte et responsable. Venez en découvrir plus en écoutant cet épisode de Trajectoire(s) aux rayons X.

In a conversation with CancerNetwork®, Nader Sanai, MD discussed the current state of the glioblastoma field, highlighting ongoing research efforts to help improve outcomes among patients with this disease.  Sanai is the director of the Ivy Brain Tumor Center and J.N Harber Professor of Neurological Surgery, Francis and Dionne Najafi chair for Neurosurgical Oncology, and chief of neurological oncology at Barrow Neurological Institute. Specifically, Sanai described plans to assess treatment with niraparib (Zejula) compared with temozolomide (Temodar) in a population of patients with newly diagnosed MGMT unmethylated glioblastoma as part of the phase 3 Gliofocus study (NCT06388733).1 He contextualized the rationale for conducting this study by focusing on findings from a proof-of-concept hybrid study (NCT05076513) and detailing how they supported additional investigation into the utility of niraparib.  According to findings from this proof-of-concept study presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, the median overall survival (OS) was 20.3 months among patients who received niraparib in combination with radiotherapy.2 Additionally, data showed that niraparib reached drug concentrations in Gadolinium-nonenhancing newly diagnosed glioblastoma tissue exceeding those of any other evaluated PARP inhibitors; investigators identified no new safety signals after combining niraparib with radiotherapy in this population. With the Gliofocus trial, Sanai and co-investigators aim to provide a clinically meaningful quality of life benefit with niraparib-based therapy beyond a marginally valuable statistical advantage. By evaluating treatment with niraparib, investigators look to improve historical survival rates reported with standard-of-care options among patients with unmethylated disease. “What we're looking to do with this trial is set a benchmark that's clinically relevant for patients and providers. The [OS] target for the study is 18 months, which is to effectively convert [a] 12-month natural history to a natural history closer to the methylated glioblastoma population,” Sanai said. “We think that is a meaningful transformation of a difficult patient population, a significant chunk of survival time that would be beneficial to patients, providers, and caregivers. Importantly, [it may also mean] an advantage for quality of life, which is of paramount importance for this patient population.” References 1.        A study comparing niraparib with temozolomide in adult participants with newly-diagnosed, MGMT unmethylated glioblastoma. ClinicalTrials.gov. Updated June 24, 2024. Accessed September 16, 2024. https://tinyurl.com/y25er8p9 2.        Sanai N, Umemura Y, Margaryan T, et al. Niraparib efficacy in patients with newly-diagnosed glioblastoma: Clinical readout of a phase 0/2 "trigger" trial. J Clin Oncol. 2024;42(suppl 16):2002. doi:10.1200/JCO.2024.42.16_suppl.2002

Voyageur Pharmaceuticals CEO Brent Willis joined Steve Darling from Proactive to announce the successful completion of formulation work for the company's latest product line, which includes five Health Canada-licensed products. These advanced formulations are set to raise industry standards, offering enhanced value to healthcare providers and stakeholders. Willis also revealed the launch of two new product brands, Vision and Smooth barium contrast agents, aimed at improving versatility and performance in medical diagnostics. Classified as new drugs, these innovative products are poised to benefit from faster approval processes, significantly reducing costs and timelines compared to traditional New Drug Application (NDA) submissions. This move marks a shift away from generics, positioning Voyageur Pharmaceuticals as a more competitive force in the market. Voyageur has already completed several pilot test batches for its product suite and is now advancing to patient testing. The company is entering the final phase of clinical trials, where these products will be used in X-ray and Computed Tomography procedures, signaling significant progress toward full market deployment. Additionally, the company has appointed Dr. Iryna Saranchova as its new Chief Science Officer, pending regulatory approval. Dr. Saranchova is a recognized expert in clinical research and immunology, with a distinguished career that includes roles as Honorary Professor/Lecturer at the University of British Columbia's Faculty of Medicine and Research Fellow at the Michael Smith Laboratories and Vancouver Prostate Center. Her expertise in biomarker discovery, clinical research, and immunotherapy development will be a key asset as Voyageur accelerates its scientific initiatives. #proactiveinvestors #voyageurpharmaceuticalsltd #tsxv #vm #vyyrf #ctscan #xray #BrentWillis, #RainCage, #Nanoscience, #MRI, #CTScan, #MedicalBreakthrough, #Fullerenes, #Vanadium, #Gadolinium, #Bismuth, #Iodine, #Radiology, #MedicalInnovation, #DrugDevelopment, #Healthcare, #ScientificBreakthrough, #Nanotechnology, #MedicalResearch, #Pharmaceuticals #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Join Ben and Rahul for their discussion with Jake and Tor, breaking down the recent 495 million Dollar verdict in a product liability case against Abbott Laboratories for pre-term infant formula that increases the risks for developing necrotizing enterocolitis. Hear how Jake and Tor navigated this difficult case and won this epic battle. About Jacob Plattenbergerhttps://www.torhoermanlaw.com/team/jake-plattenberger/Jacob Plattenberger has taken hundreds of depositions, argued in countless hearings, and tried over 35 cases to a jury.His experience in and out of the courtroom has made him a passionate advocate for those injured due to the negligence of others.Jake started his career trying cases at one of the busiest civil courthouses in the country – the Richard J. Daley Center in downtown Chicago.He started out doing insurance defense because he knew that afforded him the best opportunity to get courtroom experience.“When I was working on the defense side, I always knew that I was going to be a plaintiff's lawyer. I knew that being able and willing to try a case to a jury was a skill that I needed to have if I was going to be able to offer my clients the best legal representation. Insurance companies and corporate defendants need to believe you when you say you will take them to trial – they need to fear that.”This type of real trial experience is exceedingly rare in complex civil litigation and having seen it from the defense side gives Jake an added advantage.At TorHoerman Law, Jake manages our Chicago office where he leads trial teams in nationwide, complex litigations such as:Representing dozens of workers across the United States who were exposed to Diacetyl at work and now suffer lung diseaseeg. The Juul/E-cigarette LitigationThe Incretin Mimetics Products Liability Litigation, currently pending in the Southern District of California, where he was named to the Plaintiff's Steering CommitteeVarious Transvaginal Mesh multidistrict litigations that are currently pendingJake also maintains a personal injury practice in Chicago, representing people and their families who have been victims of catastrophic auto and truck accidents, products liability, maritime accidents, premises liability, and medical negligence.Jake believes that to successfully represent his clients, it is absolutely necessary to get personally involved.Jake's quote below perfectly reflects that belief! Notable Cases & ResultsIncretin Mimetics – Products Liability Litigation, MDL Case No. 13MD2452 AJB (MDD). Appointed to the Plaintiff's Steering Committee by Judge Battaglia in the MDL. The case is pending.JUUL E-Cigarettes – Products Liability Litigation, JCCP No. 5052. Appointed to the Plaintiff's Steering Committee by Judge Anne Jones in the JCCP. The case is pending.Diacetyl – Leads the Diacetyl litigation for TorHoerman Law. Previous settlements and verdicts have exceeded $5,000,000.00 to date. Litigation is currently ongoing.Actos Related Cases, MDL Case No. 11 L 10011, Et. Al. – Actively participated in managing the case for TorHoerman Law which resulted in a $2.4 billion settlement.Gadolinium-based Contrast Agents Litigation Case No. 279 and Products Liability Litigation MDL No. 1909 – Managed the cases for TorHoerman Law which resulted in a large, confidential settlement.Bus Accident – Handled a bus accident injury case in which an individual was thrown from a seat. Resulted in a $850,000.00 settlement.Auto Accident – Handled an auto accident injury case that resulted in a $650,000.00 settlement.Slip and Fall – Handled a slip and fall accident that occurred on a sightseeing boat in Chicago. Resulted in a $490,000.00 settlement. Personal LifeJake was born and raised in Chicago.He now lives in the Chicago suburbs, where his two young sons keep him busy.When he isn't working, Jake is a lifelong Bears and Cubs fan and loves participating in the (mostly) healthy rivalry between the Cubs and Cardinals fans at TorHoerman Law.   About Tor Hoermanhttps://www.torhoermanlaw.com/team/tor-hoerman/Tor Hoerman is a nationally recognized attorney who has served in the field for more than 25 years.He is most well-known as the founder of the personal injury law firm TorHoerman Law, LLC (THL). Early Life & EducationTor was born the youngest of four boys on July 16, 1969, in Bethesda, Maryland to Kirk and Greta Hoerman.With his father serving as a Captain in the Navy, Tor often moved towns during his childhood, eventually landing in the Chicago metropolitan area.In Chicago, Tor lived in the Great Lakes Naval Base and Lake Bluff before his family settled in Lake Forest, which is where he attended high school.Despite repeatedly switching homes, Tor made the most of his situation.In high school, he played football, basketball, and baseball, and he earned varsity letters in each of these sports.In addition to varsity recognition, he was recognized as an All-county athlete and awarded the Booster Club Athlete of the Year his senior year.Outside of sports, Tor coached little league baseball, served as a summer camp counselor, and worked as a summertime janitor at his former high school after graduating.Tor attended Depauw University and majored in Political Science.He played NCAA baseball and football at Depauw, and he was the captain of the baseball team.After graduating from Depauw in 1991, Tor enrolled in the Chicago-Kent College of Law.During law school, Tor bartended at a local bar and clerked for Kravolec, Jambois & Schwartz, LLC. Legal CareerAfter graduating from law school in 1995, Tor took on a job doing insurance defense at Bolero, Cart & Stone, LLC, where he worked reluctantly for a year and a half.One day at work, Tor received a phone call from Steve Jambois, his former employer throughout law school, asking if he wanted a job on the plaintiff's side of insurance law.Tor immediately accepted the job, kickstarting decades to come of fighting corporations on behalf of harmed individuals.Tor's Transition to Medical Malpractice LitigationTor returned to Kravolec, Jambois & Schwartz to fight on behalf of medical malpractice victims, which mostly consisted of high-intensity trial work in the Chicago courthouse.After seven years at the Jambois firm, Hoeman was recruited by the Simmons law firm, based in an Illinois suburb of St. Louis, to start and lead a branch of the practice that focused on pharmaceutical litigation.Leading the Pharmaceutical Practice at Simmons Law FirmTor became a partner of what is now Simmons, Hanly, and Conroy and led the pharmaceutical practice for seven years.One of Tor most notable achievements while leading the practice was his work against Purdue Pharma and its reckless distribution of OxyContin.Tor was the first to file a case alleging Purdue Pharma's wrongdoing in distributing OxyContin and failing to adequately warn healthcare providers and the public of the risks of addiction.Achieving Justice Against Purdue PharmaHe led the litigation process and got Purdue Pharma to agree to a large settlement, which was distributed to thousands of accidental addicts.Tor took a step further to achieve justice in this case, assisting the Department of Justice in obtaining guilty pleas by Purdue Pharma representatives who had a direct role in contributing to the opioid epidemic. Founding TorHoerman LawHaving garnered success leading the pharmaceutical branch at the Simmons firm, Tor amicably decided to split from Simmons in 2009 and start his own pharmaceutical and personal injury practice called TorHoerman Law, LLC (THL).After negotiating the terms of the split, Tor struck a deal that allowed him to bring his entire staff from Simmons to his new practice, which summed up to more than 25 lawyers and staff members.Expansion and Success of THLTor opened offices in Edwardsville, IL; Clayton, MO; and Chicago, IL to kickstart operations; all three offices remain open today.In the time since opening THL, Tor and his team have litigated many pharmaceutical malpractice and personal injury cases.Notable Successes at THLTor's most notable successes while operating THL are perhaps co-leading the litigations against Boehringer Ingelheim's Pradaxa and Takeda's Actos.Through intense research and vetting, Tor was able to find substantial evidence indicating Actos causes bladder cancer and Pradaxa causes internal bleeding.He then presented the evidence to the companies, which decided to settle the cases.Tor played a significant role in negotiating these settlements, which ended up being $650 million for Pradaxa and $2.4 billion for Actos.Tor has also had major success in several other product liability lawsuits, such as Zelnorm, Gadolinium-based Contrast Agents, and Incretin Mimetics.We've outlined these cases, a few other notable cases, and their correlating results in the section below.Recognition & AwardsHis successes with these cases and beyond earned him the distinction as a Top 25 Notable Alumni from the Chicago-Kent School of Law, which was awarded to him and 24 other lawyers out of the tens of thousands who have graduated from the school since its founding in 1888.Tor is also recognized as a Top 100 National Trial Lawyer by the National Trial Lawyers Organization. Notable Cases & ResultsPradaxa (Dabigatran Etexilate) – Products Liability Litigation, MDL 2385 – Appointed by Judge Herndon as national lead counsel in the MDL. After protracted litigation successfully negotiated a $650 million settlement.Actos Related Cases, MDL Case No. 11 L 10011, Et. Al. – Appointed by Judge Dooling as lead counsel in Cook County consolidated docket (over 4400 cases). After protracted litigation, he was one of four lead negotiators (along with Pete Flowers, Mark Lanier, and Andy Birchfield) on a $2.4 billion settlement.Incretin Mimetics Products Liability Litigation, MDL Case No. 13MD2452 AJB (MDD) – Appointed as lead counsel by Judge Battaglia in the MDL. The case is pending.OxyContin – Represented thousands of “accidental addicts”. After protracted litigation, he negotiated a large settlement and assisted the DOJ in obtaining guilty pleas by corporate representatives.Zelnorm Litigation., Case No. 280 – Appointed lead counsel in NJ state court consolidation, took the major depositions and negotiated a confidential settlement.Gadolinium-based Contrast Agents Litigation Case No. 279 and Products Liability Litigation MDL No. 1909 – Appointed by Judge Polster as both the state and federal liaison and lead counsel in the Cook County consolidated docket. He negotiated large, confidential, individual settlements. Involvement in the Legal CommunityIn addition to his litigation work, Tor is on the Board of Managers of the Illinois Trial Lawyer Association and an Executive Board Member of the Mass Torts Trial Lawyer Association.He also attends national legal conferences on a yearly basis. Personal LifePersonally, Tor is the proud father of Casey, Kirsten and Quinn, and husband of Jessica.He tries to stay active, including still playing baseball.

AKI Tips and Tricks from Joel Topf MD, Kashlak's Chief of Nephrology Get a grip on acute kidney injury (AKI) with Dr. Joel Topf (AKA @kidney_boy), Kashlak's Chief of Nephrology! We've put together an AKI highlight reel - focusing on practical tips and tricks to help you identify, diagnose and manage AKI, plus how to recognize AIN and random myths and musings on vancomycin, NSAIDS, contrast nephropathy, and the risk of NSF from gadolinium. Listeners can claim Free CE credit through VCU Health at http://curbsiders.vcuhealth.org/ (CME goes live at 0900 ET on the episode's release date).  Show Notes | Subscribe | Spotify | Swag! | Top Picks | Mailing List | thecurbsiders@gmail.com | Free CME! Credits Written (including CME questions) and Produced by: Cyrus Askin, MD Infographic by: Cyrus Askin, MD Cover Art: Kate Grant MBChb, MRCGP Hosts: Matthew Watto MD, FACP; Paul Williams MD, FACP    Editor: Matthew Watto MD, FACP (written materials); Clair Morgan of nodderly.com Guest: Joel Topf, MD Time Stamps 00:00 Sponsors - VCU Health CE and Pediatrics On Call podcast by APP 00:30 Intro, disclaimer, guest bio 03:00 Guest one-liner, Picks of the Week*: Zoe Keating albums (Cellist); Mrs. America (TV series) on FX; The Last of Us (Videogame); 08:45 Sponsor - Pediatrics On Call podcast by APP 09:15 Definition of acute kidney injury (AKI) and fundamentals 11:00 Cardiorenal syndrome 12:24 Schema for AKI 17:30 Establish an etiology, determine urine output and address electrolyte abnormalities 21:22 AKI in the otherwise-healthy patient; 32:20 Rhabdomyolysis
38:21 Vancomycin 41:43 Acute interstitial nephritis (AIN) 44:52 Contrast induced nephropathy (CIN) 50:37 Gadolinium in AKI and/or CKD 52:53 Timing of dialysis 
 56:37 AKI in the out-patient setting and how to handle home meds e.g. TMP-SMX, RAAS inhibitors; 62:01 Is Ultrasound necessary in AKI
 64:58 Dr. Topf's take home points and Plug for Seminars in Nephrology 68:45 Outro and Sponsor - VCU Health CE Sponsor: Freed You can try Freed for free right now by going to freed.ai. And listeners of Curbsiders can use code CURB50 for $50 off their first month. Sponsor: Panacea Financial If you're ready to join the thousands of doctors who have declared independence from traditional banks, visit panaceafinancial.com today. Sponsor: Locumstory Tune in to The Locumstory Podcast on Spotify, Apple, or Google podcasts.

Bill Faulkner and Dr Manny Kanal discuss gadolinium-based contrast agents Click Here to  Claim your Credit This MR iCast episode is supported by Bracco Diagnostics Inc. through an unrestricted educational grant.

Why You Should Listen:  In this episode, you will learn above the role of gadolinium in chronic conditions and about the entity of Gadolinium Deposition Disease. About My Guest: My guest for this episode is Dr. Richard Semelka.  Richard Semelka, MD has been in practice as a radiologist for 28 years and is a world authority in body MRI, safety in radiology, and gadolinium toxicity.  He is a leading published expert in radiology for body MRI and gadolinium toxicity and has made presentations at major meetings all over the world.  Dr. Semelka has written over 370 peer-reviewed papers and 16 text-books.  He is the first doctor to publish on the entity of Gadolinium Deposition Disease. Key Takeaways: What is gadolinium? What are the symptoms of Gadolinium Deposition Disease? Are certain populations at higher risk for GDD than others? Should gadolinium be treated before the immune priming event? How is gadolinium tested for? What is the primary route of gadolinium excretion? Are the symptoms toxigenic or immunogenic? Does gadolinium cross the blood brain barrier? Does gadolinium have an effect on the mast cells? How does gadolinium impact the mitochondria? Is there a correlation between methylation and response to gadolinium? Is supporting drainage pathways important? What are GAD removal and re-equilibration flares? How is gadolinium chelated from the body? Can glutathione be helpful in addressing gadolinium toxicity? Is there a role for sauna therapy? Connect With My Guest:  http://RichardSemelka.com Interview Date: July 10, 2024 Transcript: To review a transcript of this show, visit https://BetterHealthGuy.com/Episode203. Additional Information: To learn more, visit https://BetterHealthGuy.com. Disclaimer:  The content of this show is for informational purposes only and is not intended to diagnose, treat, or cure any illness or medical condition. Nothing in today's discussion is meant to serve as medical advice or as information to facilitate self-treatment. As always, please discuss any potential health-related decisions with your own personal medical authority. 

Voyageur Pharmaceuticals CEO Brent Willis joined Steve Darling from Proactive to announce that the company and Rain Cage Carbon are advancing their collaboration following the first commercial creation of a V@C60 endohedral fullerene or Vanadium atom inside a C60 molecule. Rain Cage is now embarking on the next phase of radiology drug development using their cutting-edge technology. Willis told Proactive that Rain Cage will begin working to create on a commercial scale, the encapsulation of gadolinium, bismuth, and iodine within endohedral fullerenes. This pioneering work, set to begin later this month, aims to develop a process to create Gd@C60, Bi@C60, and I@C60 endohedral fullerenes, targeting the development of highly advanced radiology contrast agents for Magnetic Resonance Imaging (MRI) and CT scans. These novel compounds, known for their rarity and complex synthesis, hold the promise of transforming medical imaging by significantly enhancing the precision and clarity of radiological scans. Endohedral fullerenes are a class of fullerenes that enclose an additional atom, ion, or cluster within their inner sphere, exhibiting superior physical and electronic characteristics compared to regular fullerenes. In the context of radiology drugs, endohedral metallofullerenes offer distinct advantages through exceptional stability and bioavailability, an amplified signal that leads to better image clarity and resolution, targeted delivery, and reduced toxicity. These properties have garnered interest in applications such as MRI contrast agents #proactiveinvestors #voyageurpharmaceuticalsltd #tsxv #vm #vyyrf #ctscan #xray #BrentWillis, #RainCage, #Nanoscience, #MRI, #CTScan, #MedicalBreakthrough, #Fullerenes, #Vanadium, #Gadolinium, #Bismuth, #Iodine, #Radiology, #MedicalInnovation, #DrugDevelopment, #Healthcare, #ScientificBreakthrough, #Nanotechnology, #MedicalResearch, #Pharmaceuticals #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt joined Proactive's Stephen Gunnion with news of the publication of extended data from the Phase 2 EMPhASIS trial of vidofludimus calcium in relapsing-remitting multiple sclerosis (RRMS) in the peer-reviewed journal, Neurology® Neuroimmunology & Neuroinflammation, an official journal of the American Academy of Neurology. Vitt noted that the EMPhASIS trial demonstrated a notable reduction in gadolinium-enhancing lesions by 78% and 74% in two high-dose groups compared with the placebo. These results also correlate with improvements in serum neurofilament light chain levels, consistent with recent interim phase 2 clinical data from the ongoing CALLIPER trial in progressive MS, indicating ongoing progress in the field. Vitt highlighted the study's contribution to understanding the neuroprotective and anti-inflammatory effects of the treatment under investigation. The drug's potential impact on the treatment landscape of MS, particularly its role in addressing disease progression independent of relapse activity, was emphasized. Immunic is also conducting the CALLIPER trial in progressive MS, with key results expected by April 2025. Additionally, the phase 3 ENSURE trials are actively enrolling, with projected readouts in 2026. Dr Vitt expressed optimism about the drug's unique profile, combining safety and effectiveness in potentially altering the management of all forms of MS. #ImmunicInc, #DrDanielVitt, #EMPHASISTrial, #MultipleSclerosis, #MSResearch, #Neurology, #ClinicalTrials, #Phase2, #Phase3, #DrugDevelopment, #MedicalInnovation, #Neuroprotection, #AntiInflammatory, #Healthcare, #MedicalJournal, #AmericanAcademyOfNeurology, #Gadolinium, #SerumNeurofilament, #ProgressiveMS, #NeurodegenerativeDiseases #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Gadolinium is a toxic rare earth metal commonly used as a contrast agent in medical scans. Doctors love it because it makes bones and muscles glow in the dark. However, autopsy reports have proved that the body retains gadolinium for years!     Many patients experience severe symptoms after gadolinium injections without knowing the root cause. Unfortunately, no FDA-approved cure or antidote is currently available. Today's guest is among the people living with the effects of gadolinium poisoning.      Debbie Heist Lambert, founder of Living with Gadolinium, has spent thousands of hours researching this condition that caused her near-death experience and dementia. She shares valuable insights on the symptoms of gadolinium retention, such as brain fog, neuropathy, bone pain, autoimmune diseases, and skin conditions.      Debbie advocates for patients to exercise their right to informed consent before a gadolinium injection. Affected patients need proper detoxification and chelation to relieve the symptoms, and they need community support.     Tune in to learn about the types of medical scans that use gadolinium and your options as a patient.        “If you've been injected with gadolinium, you're retaining some. Whether or not you have a lot of symptoms and a lot of problems, that's to be determined.” -  Debbie Heist Lambert   Today's Episode Explores: - What is gadolinium? - What are the symptoms of gadolinium toxicity? - Advocacy and support for gadolinium toxicity patients - Types of medical scans that use and don't use gadolinium  - Why patients develop severe gadolinium-related issues  - A patient's options when getting a medical scan - Challenges in the diagnosis of gadolinium poisoning - Detoxification and treatment options for gadolinium toxicity  For more information, visit www.myersdetox.com/gadolinium     After listening to this episode, you might be wondering about heavy metals. You can take my quiz here for more info: heavymetalsquiz.com    About Debbie Heist Lambert: Debbie Heist Lambert, founder of Living with Gadolinium, advocates for all medically injured patients. Debbie holds a BA from George Fox University. She graduated with a Certificate as a Functional Nutrition Counselor in 2022. Debbie is enthusiastic about ensuring informed consent, truth, and transparency become the gold standard for healthcare. After her experience following multiple injections of Gadolinium contrast dye, Debbie found passion and purpose in learning and applying new knowledge to help herself heal and provide support and help to others.    Join Debbie's Facebook Gadolinium advocacy group at https://www.facebook.com/groups/1431383276922546 and follow her Facebook page https://www.facebook.com/livingwithgadadmin.    Disclaimer The Myers Detox Podcast was created and hosted by Dr. Wendy Myers. This podcast is for information purposes only. Statements and views expressed on this podcast are not medical advice. This podcast, including Wendy Myers and the producers, disclaims responsibility for any possible adverse effects from using the information contained herein. The opinions of guests are their own, and this podcast does not endorse or accept responsibility for statements made by guests. This podcast does not make any representations or warranties about guests' qualifications or credibility. Individuals on this podcast may have a direct or indirect financial interest in products or services referred to herein. If you think you have a medical problem, consult a licensed physician.  

MedLink Neurology Podcast is delighted to feature selected episodes from BrainWaves, courtesy of James E Siegler MD, its originator and host. BrainWaves is an academic audio podcast whose mission is to educate medical providers through clinical cases and topical reviews in neurology, medicine, and the humanities, and episodes originally aired from 2016 to 2021. Originally released: October 25, 2018 Every time you order an MRI with contrast, you should think to yourself, "Why do I need contrast?" Then, "If I need contrast, what are the risks?" This week's show is all about the risks of routine neuroimaging. Produced by James E Siegler. Music by Little Glass Men, Loyalty Freak Music, and Kevin McLeod. Sound effects by Mike Koenig, Daniel Simion. BrainWaves' podcasts and online content are intended for medical education only and should not be used for clinical decision-making. Be sure to follow us on Twitter @brainwavesaudio for the latest updates to the podcast. REFERENCES McDonald RJ, McDonald JS, Kallmes DF, et al. Intracranial gadolinium deposition after contrast-enhanced MR imaging. Radiology 2015;275(3):772-82. PMID 25742194Pullicino R, Radon M, Biswas S, Bhojak M, Das K. A review of the current evidence on gadolinium deposition in the brain. Clin Neuroradiol 2018;28(2):159-69. PMID 29523896Rogosnitzky M, Branch S. Gadolinium-based contrast agent toxicity: a review of known and proposed mechanisms. Biometals 2016;29(3):365-76. PMID 27053146 We believe that the principles expressed or implied in the podcast remain valid, but certain details may be superseded by evolving knowledge since the episode's original release date.

In this episode, we review the high-yield topic of ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Gadolinium-Associated Nephrogenic Systemic Fibrosis⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠from the Renal section. Follow ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets Linkedin: https://www.linkedin.com/company/medbullets

Welcome to Resiliency Radio with Dr. Jill, where we bring you the latest insights from leading experts in the field of health and wellness. In this episode, we have the honor of hosting Dr. Richard Semelka, a renowned expert on Gadolinium Toxicity. Gadolinium, a heavy metal commonly used in contrast agents for medical imaging, has been a topic of concern in recent years due to its potential health risks. During our conversation, Dr. Semelka will shed light on Gadolinium Deposition Disease (GDD) and its implications for patients who have undergone contrast-enhanced MRI scans. Key Points A small percentage of people experienced symptoms of Gadolinium Deposition Disease (GDD) or gadolinium deposition in the brain after MRI with contrast Recognize the most common symptoms of Gadolinium Deposition Disease (GDD) Optimize treatment with chelation to excrete gadolinim and other heavy metals and restore health after GDD

Happy 2024! I am ready for another year of writing about the intersections of weight science, weight stigma, and healthcare and I'm glad you are here reading! This is the Weight and Healthcare newsletter! If you like what you are reading, please consider subscribing and/or sharing!I received the following question from reader Lisa:I notice that when you write about things that can hurt larger people's health you usually mention weight cycling, weight stigma, and healthcare inequalities. I've read your posts for the first two – is there a post that describes the third one?Thanks for asking Lisa, I've been meaning to write this and you've given me the perfect gentle push! For the record the piece for the harm of weight cycling is here and the one on the harm of weight stigma is here.The idea of healthcare inequalities is difficult to quantify because it's such a vast category. In terms of a definition, the one I'm going to use here is any way in which higher-weight people's healthcare experiences differ from those of thin people to the detriment of higher-weight people.It's always important to remember that when we discuss these inequalities we are clear that they don't impact everyone equally, as people's weight becomes higher their experience of inequality typically increases as well and, utilizing Kimberlé Crenshaw's framework of intersectionality, those who have multiple marginalized identities will also face greater inequality in their individual marginalizations and at the intersections of them.Finally, I want to point out that thin people can face healthcare disparities as well based on things like marginalized identities and socioeconomic status. The comparisons I'm drawing here are about the typical experience of thin people and are not meant to indicate that thin people never face issues in accessing healthcare, just that as a group thin people are not systematically marginalized within the healthcare system because of their size.I also want to be clear that this is not an exhaustive list and I welcome you to add other examples in the comment section. I'm going to divide these up into groups to help give this conversation some structure.Practitioner BiasThis includes a lot of different things. Before I get into it, I want to point out that providers aren't necessarily bad actors who just hate fat people (though, sadly, some absolutely are.) Many are simply a product of a healthcare system (including healthcare education) that is deeply rooted in weight stigma. Regardless of how they got to this place, these practitioners are responsible for the harm that they do.Some practitioners are operating out of implicit bias, which is to say that the bias is subconscious. Others are operating from explicit bias, they are fully aware of their negative beliefs and stereotypes about higher-weight people and they are working with higher-weight patients based on those beliefs and feelings. This can lead to a lot of negative impacts. Some examples:There is the classic (and far too prevalent) example of a practitioner who offers ethical, evidence-based treatments to thin patients for health issues, but sends higher-weight patients with the same symptoms/diagnoses/complaints away with a diet.There's the “Occam's razor” mistake. Occam's Razor states “plurality should not be posited without necessity.”  Said another way, when choosing between theories, the simplest one is usually correct. This gets applied to the care of higher-weight patients when providers don't address individual health issues/symptoms/diagnoses/complaints for fat patients because they assume weight loss will solve them all (and/or they want to see what weight loss solves before attempting the ethical, evidence-based treatments that thin people would typically get for the same issues/symptoms/diagnoses/complaints.)Some practitioners assume that fat patients are lying if what they are telling the provider doesn't match up with the provider's stereotypes of people their size. These practitioners base decisions and recommendations on their stereotypes rather than what the patient is telling them.There are practitioners who, consciously or subconsciously, are reluctant to touch fat patients or manipulate their bodies which can impact everything from examinations to post-operative care.There are practitioners who think it's worth risking fat people's lives and quality of life in attempts to make them thin. Some of these practitioners take this further by deciding that they know better than fat people and so try to manipulate/trick/bully fat people into weight loss interventions (including dangerous drugs and surgeries) by almost any means necessary including intentionally failing to give a thorough informed consent conversation – blowing patients off with phrases like “all drugs have side effects” or “it's nothing to worry about” rather than being honest about the risks and/or making threats about the patient's health and life expectancy that are not supported by evidence. These inequalities can lead to many harms. First of all, we know from a century of data that weight loss almost never works and typically results in weight cycling which is independently linked to a number of harms. It can also delay care – when a thin person gets an intervention at their first appointment but a fat person with the same symptoms/diagnosis gets sent away with a recommendation to lose weight the higher-weight patient's actual care is delayed.The “Occam's Razor” mistake creates similar problems. It must be remembered that Occam (actually, it seems, Ockham but that's a whole other thing) was a philosopher, not a physician. Deciding to treat something as complex as the human body by going for the simplest strategy is problematic on its face, even before we add the ways that weight stigma impacts providers' beliefs around and treatment of higher-weight patients.And there is another layer of harm here. As we'll see over and over, the harm from healthcare inequalities is intensified when the results of the harm are blamed on fat bodies. For example, higher-weight patients follow practitioners' advice to attempt weight loss. They lose weight short term and gain it back long term (which is exactly what all the research we have says will happen.) Their doctors tell them to try again, they weight cycle again. This happens repeatedly across their entire lives. Eventually these patient are diagnosed with cardiovascular disease (CVD). The fact that CVD is strongly linked to weight cycling is completely ignored and research (often created by/for the weight loss industry) blames “ob*sity” for the CVD and uses these higher rates of CVD to lobby for greater insurance coverage of weight loss treatments and the cycle of harm continues unabated.Structural InequalitiesThis occurs when the things that higher-weight patients need in order to access healthcare don't accommodate them. This can be because the things don't exist or because the healthcare facility that the patient is visiting doesn't have them.Again, there are too many examples here to name. One very common example is chairs. Having sturdy armless chairs in the waiting room, treatment rooms, and anywhere a patient may need to sit is the absolute least a facility can do and it's deeply disturbing how many facilities don't even get this right.Then there are the absolute basics of care – when the practice doesn't have (or can't find) properly sized/accommodating blood pressure cuffs, proper length vaccine needles, gowns, scales (for medically necessary weigh-ins like those to dose medications or check for edema from a heart condition). These are all things that thin patients can typically expect to be available.Durable medical equipment is another area where structural inequalities can compromise care – crutches, braces, walkers, wheelchairs, prosthetics.  Even when these things are available, they are often exponentially more expensive even when they don't have to be custom made.Then there are more specialized tools like operating tables and surgical instruments. Often the only place these instruments can be reliably found is in centers that focus on weight loss surgeries, meaning that higher-weight patients are excluded from the kind of surgical care that is routine for thinner patients.Next is imaging -   MRI and CT scanners that have high-weight rated tables and large enough bore sizes, ultrasounds that can appropriately view through adipose tissue, x-ray tables and spaces that are accommodating and more. Harm is added here when energy from those in the healthcare system is wasted on complaining that higher-weight people exist or justifying the lack of care, rather than focusing on solutions and working from the basis that healthcare should fit bodies, bodies shouldn't have to be changed to fit healthcare.As an example of this, let's look at the ways that a single MRI appointment can create healthcare inequalities. A patient is referred for an MRI of their knee with contrast. First, the patient goes to the facility to which their doctor referred them but is turned away because the MRI is too small. They call the referring doctor, who isn't aware of any other option and tells them to call around. After hours of research they find an MRI with a 550 pound weight limit and a bore size that will accommodate them, but unlike the first facility this one has a backlog so they'll have to wait three more weeks. When they arrive for their appointment the MRI tech is using a Gadolinium-based contrast agent (GBCA). The dosage table the tech has stops at 300 pounds and the patient says that they weigh more than that. So the tech decides to use a GBCA calculator, using the formula of the recommended dose (mmol/kg) multiplied by weight (kg) and divided by concentration (mmol/mL). Except the scale in the MRI facility has a limit of 400 pounds which is less than this patient weighs. The tech explains the risk of incorrect dosage and tells the patient that they can either cancel the MRI or give the tech their best guess of their weight. The patient offers their best guess. The patient is given a gown to change into, but it's way too small. The patient is told that they don't have gowns that are any bigger. The patient offers to wear their own clothes, explaining that they have worn 100% cotton clothes for exactly this reason. They are told that it's against policy and that the tech will have to ask their boss. The boss is off today so the patient can be rescheduled in 3 weeks and the tech says he will “try to remember” to ask his boss about the patient wearing their own clothes but suggests that the patient keep calling to try to verify and also that the patient find a scale that works for them so that they can give the tech an accurate weight. The patient comes back in three weeks with an accurate weight and having confirmed that they can wear their own clothes. They lay down on the MRI table and the tech tries to put the knee in the dedicated knee coil that allows the MRI to view the knee structure. It is too small for the patient's leg. The patient is told that there is no way to get an MRI of their knee.This is just one scan for one patient, and this is based on a true story. The failure of the healthcare system to accommodate higher-weight patients has the potential for a massive amount of harm, most of which goes uncaptured or, worse, is blamed on “ob*sity.”Research BiasThis also happens in multiple ways. It can include higher-weight people being left out of research. For example, it is well known that clearance rates of some anesthesia drugs can vary based on the amount of adipose-tissue a patient has, but higher-weight patients have traditionally been excluded from the trials for anesthesia medications so there isn't good data on this.Here harm is also increased when naming the inequality is seen as sufficient remedy. I recently spoke at the combined conference for the Washington State Society of Anesthesiologists and British Columbia Anesthesiologists' Society (which was an absolute delight! I gave a keynote and then had the honor of being on a panel with Dr. Lisa Erlanger and Dr. Sandi Pitfield.) In preparation for this, I read hundreds of pages of anesthesia research. What I repeatedly found were decades of studies that started by saying that higher-weight patients' exclusion from drug trials created serious knowledge gaps, but then just moved on. Admitting that there is a problem is the first step, it must be followed by taking steps to solve the problem. The solution is not to cobble together what exists and keep creating guidelines based on shoddy research.Part of this issue is researcher bias, limitations of time and money, and perceptions that it's not worth studying fat people or that it's reasonable for fat people to be excluded from research (often under the guise that it's acceptable to make fat patients become thin before they can access ethical, evidence-based medicine.)Another issue is the massive amount of money that is earmarked only to study the prevention and/or eradication of fatness instead of researching how to actually support the health of fat people.It Seems Like A Lot…This happens when we actually do know what fat patients need, for example, in terms of dosage. But they are still under-medicated because the amount that higher-weight people need “seems like a lot” to those who are dosing the drugs and who are used to the dosage for thinner patients.When someone's education is focused on thin patients (including viewing thin patients as “normal” and higher-weight patients as “different/abnormal/extra” and the treatment protocols for thin patients are the focus, then those practitioners can balk at what higher-weight patients actually need.Risk predicated on sizeThis happens when patients who are higher-weight are given treatments that are more dangerous based on their size alone. In an example I wrote about more in depth here, thin patients with type 2 diabetes are not referred to weight loss surgeries that create a permanent disease state in their digestive systems, carry extensive risk, and have very little long-term term data. Patients with so-called “class 1 ob*sity” have the surgery offered if they can't reach their glycemic management goals. Those with so-called “class 2 ob*sity” have the surgery “recommended” if they can't reach their glycemic management goals. Patients with so-called “class 3 ob*sity” have the surgery “recommended” regardless of their glycemic management. Even if someone believes that these surgeries meet the requirements of ethical, evidence-based medicine, the reality is that they are risky and suggesting that someone with well-controlled type 2 diabetes have a dangerous surgery simply because of their size is another dangerous healthcare inequality.BMI-Based Denials of CareI've written about these, and options to fight them, quite a bit (this is a good place to start). This occurs when a fat patient is denied healthcare (often a surgical procedure) unless or until they change their height-weight ratio. These denials are often “justified” using rationale that comes from blaming fat bodies for the negative outcomes of weight stigma, weight cycling, and other healthcare inequalities (for example, as I wrote about above, higher rates of post-op complications) and they amount to holding healthcare hostage for a weight loss ransom (and a ransom that most people will not be able to pay.) While all of the denied procedures are important, in some cases (like some organ transplants,) the procedures that are denied are truly life or death.Saving Money Through Healthcare InequalitiesA common attempted “justification” for the healthcare inequalities that fat people face is the idea that fat people shouldn't get the resources they need if they happen to need more resources than the average thin person. When added to a general focus on profit (especially in the US healthcare system) this leads to staff-to-patient ratios that make it impossible to correctly care for fat patients (for example, having adequate staff to safely turn patients to prevent bed sores or help them ambulate to improve post-surgery outcomes.) It can also mean not having the supplies that these patients need in order to have the best outcomes. Some examples are InterDry to prevent/treat skin fold infections or Hoyer lifts so that they can use a commode and avoid bedpans and chuck changes (both of which are made more difficult and dangerous for the patient and more likely to create negative outcomes when staff-to-patient ratios don't allow for adequate care, even if the practitioners aren't coming from a place of weight bias.)All of this, in turn, can create practitioner bias when they blame higher-weight patients rather than the healthcare system that is leaving both patients and practitioners without what they need.   When healthcare facilities are allowed to decide that they don't want to spend the money to give higher-weight people the care they need, or they are not adequately funded to do so, then higher-weight patients suffer. Here again the negative impacts of this are often simply blamed on “ob*sity.” For example, research on post-operative complication rates will often suggest that “ob*sity” causes higher complication rates without exploring the ways that these size-based healthcare inequalities may actually be at the root of any elevated rate of complications.This is not an exhaustive list of healthcare inequalities that higher-weight people face (please feel free to add other examples in the comments.) I'll also say that this is made much worse because these harms are not adequately measured or remedied and the harms from them get attributed to “ob*sity” rather than the inequalities that higher-weight people face.Did you find this post helpful? You can subscribe for free to get future posts delivered direct to your inbox, or choose a paid subscription to support the newsletter (and the work that goes into it!) and get special benefits! Click the Subscribe button below for details:Liked the piece? Share the piece!More research and resources:https://haeshealthsheets.com/resources/*Note on language: I use “fat” as a neutral descriptor as used by the fat activist community, I use “ob*se” and “overw*ight” to acknowledge that these are terms that were created to medicalize and pathologize fat bodies, with roots in racism and specifically anti-Blackness. Please read Sabrina Strings' Fearing the Black Body – the Racial Origins of Fat Phobia and Da'Shaun Harrison's Belly of the Beast: The Politics of Anti-Fatness as Anti-Blackness for more on this. Get full access to Weight and Healthcare at weightandhealthcare.substack.com/subscribe

Overlæge på Hvidovre Hospital Einer Kragh står i lidt af et dilemma. Han har modtaget et enormt generøst tilbud fra rejsekongen Simon Spies som tak for god behandling. Hvad mangler Hvidovre Hospital, og hvad kan bedst komme patienterne til gavn? Da først Einer Kragh modtager donationen, er Simon Spies gået bort. Men ikke desto mindre har en af hans sidste akt ændret markant, hvordan det danske syghusvæsen så ud for 40 år siden.Periodisk – en RAKKERPAK Original af Rakkerpak Productions.Historierne du hører bygger på journalistisk research og fakta. De kan indeholde fiktive elementer som for eksempel dialog.Hvis du kan lide min fortælling, så husk at gå ind og abonnér, give en anmeldelse og fortæl dine venner om Periodisk.Podcasten er blevet til med støtte fra Novo Nordisk Fonden. Hvis du vil vide mere kan du besøge vores website periodisk.dkAfsnittet er skrevet og tilrettelagt af Mads G. LadekarlTor Arnbjørn og Dorte Palle er producereMartin Birket-Smith står for lyddesign og mixSimon Bennebjerg er vært

Step into the powerful realm of MRI imaging, providing us with an unparalleled view of multiple sclerosis. Discover how acute inflammation becomes vivid with contrast, and how various MRI sequences unveil the past battles fought within your brain and spinal cord. We'll explore advances in techniques, revealing brain shrinkage, gray matter disease and myelin repair. Understand the impact of MS on brain processing efficiency during rest and specific tasks through functional MRI imaging. Crucial questions regarding where and how often to get MRI scans are addressed. Latest guidance on avoiding contrast for routine MRI monitoring in MS shared. Barry Singer MD, Director of The MS Center for Innovations in Care, interviews: Christina Azevedo MD, Assistant Professor of Clinical Neurology at the University of Southern California Robert Zivandinov MD, PhD, Director of the Buffalo Neuroimaging Analysis Center & Professor of Neurology at Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo, State University of New York.

Nurses Out Loud with Kimberly Overton, BSN, RN – Gadolinium toxicity is a concerning issue that needs to be given our utmost attention. Gadolinium is a contrast agent commonly used in medical imaging procedures, despite the fact that it has been found to have potentially harmful effects on the human body. The use of gadolinium-based contrast agents in MRI scans has revolutionized the field of diagnostic medicine. However...

Nurses Out Loud with Kimberly Overton, BSN, RN – Gadolinium toxicity is a concerning issue that needs to be given our utmost attention. Gadolinium is a contrast agent commonly used in medical imaging procedures, despite the fact that it has been found to have potentially harmful effects on the human body. The use of gadolinium-based contrast agents in MRI scans has revolutionized the field of diagnostic medicine. However...

Mikroplastik, Glyphosat, Schwermetalle, Pestizide: Wir alle sind vergiftet, leider eher mehr als weniger. Andreas Breitfeld mit dem inneren Putzprogramm von Aktivkohle bis Glutathion, von NAC bis NAD, von Chlorella bis Zeolith, von Apherese bis Sauna. Der Sponsor dieser Folge ist Blinkist. Hol dir den Blinkist Premium Account mit 25% Ermäßigung auf https://www.blinkist.com/biohacking Probleme mit Gadolinium? Eine hyperbare Sauerstoffkammer (zum Beispiel die in Andreas Breitfelds Biohacking-Lab in München) könnte helfen. Die Entgiftung generell unterstützen können: • Aktivkohle (problemlos überall im Internet oder in der Apotheke) • Medizinische Kohle (aus grünen Kaffeebohnen), z.B. hier: https://www.hevert.com/market-de/de/arzneimittel/arzneimittel_von_a-z/produkt/kohle-hevert• Zeolith, z.B. hier: https://www.biosa-vitalkonzepte.de/ZeolithMED-Detox-Pulver-gepruefte-Medizinqualitaet-400g• Quicksilver Scientific Push & Catch gibt es hier: https://www.functionalself.co.uk/quicksilver-scientific-liver-saucer.html• Chlorella, aktuell (Stand Oktober 2022) sauber sollte diese sein: https://www.amazon.de/dp/B01NGTJYHV/ Ansonsten gilt https://www.heidelberger-chlorella.de als gute Adresse für all die genannten Entgiftungstinkturen, wie eben Chlorella, aber auch Bentonit, Koriander etc. Andreas Breitfeld setzt sie selbst in der Arbeit mit seinen – meist fortgeschrittenen – Klientinnen und Klienten aber nicht ein. • Ob man NR also Nicotinamide, NMN oder NAD+ verwendet, hängt von Budget und Level der Energielosigkeit ab. NR ist relativ günstig, braucht aber länger bis es zu wirken beginnt: https://www.sunday.de/vitamin-b3-niacin-nicotinamid-500mg-kapseln-hochdosiert.html; NMN ist ein paar Protonen reicher, geht schneller, kostet aber schon mehr: https://www.moleqlar.de/produkt/uthever-nmn/ (mit Code a.breitfeld aber 10% weniger); NAD+ als Infusion gibt's z.B. bei https://www.burn-out-muenchen.de/standorte/index.html Liposomales Glutathion gibt es bei Mitocare: https://mitocare.de/products/lipo-glutathion-booster • Um Glutathion selbst basteln zu können, braucht der Körper 3 Aminosäuren, welche es alle unter anderem bei https://edubily.de gibt. 1.) Cystein, z.B. https://edubily.de/products/n-acetyl-l-cystein2.) Glutamin, https://edubily.de/products/glutamin-pulver3.) Glycin, https://edubily.de/products/glycin-pulver EinläufeEin vernünftiges Gerät für den Einstieg ist zum Beispiel dieses: https://www.amazon.de/Magent-Edelstahl-Darmeinlauf-Irrigator-Darmreinigung-Verstopfung/dp/B08TQJMWMP Bernd Stösslein ist Experte in der Sache. Hier Bernds Anleitung für den Kaffee-Einlauf: https://www.bernd-stoesslein.de/tag/kaffee-einlauf/Sein YouTube-Kanal: https://www.youtube.com/c/BerndStoesslein Infos zu Chelattherapie und EDTA-Therapie hier: https://www.chelattherapeuten.com/chelattherapie/ Apherese? Das Thema ist ein Dschungel, in dem sehr gerne sehr viel versprochen und nicht ganz so viel gehalten wird. Bei ernsthaftem Interesse gerne den Andreas direkt kontaktieren, er hat sich mit dem Thema intensiv beschäftigt. Andreas Breitfelds Website: https://breitfeld-biohacking.com Das ausführliche Porträt über Andreas Breitfeld in The Red Bulletin (Autor, übrigens: Stefan Wagner): https://www.redbull.com/at-de/theredbulletin/biohacking-andreas-breitfeld Das Biohacking-Special, das Andreas Breitfeld und Stefan Wagner gemeinsam für The Red Bulletin Innovator produziert haben: https://issuu.com/redbulletin.com/docs/0221_trbi_at_lowres Stefan Wagners Biohacking-Kolumne im „carpe diem“: https://www.carpediem.life/wagner

KSQD 10-19-2022: Another Gene of the Week -- the detoxification gene COMT; New nutrition formula that supports the microbiome greatly improves malnutrition treatment; How to judge PSA levels and the risks for prostate cancer; Risks of gadolinium in contrast imaging and other heavy metal risks; The role of iodine in reducing breast cancer; Hormone disruptors in water-proof makeup products; Cleaning kitchen surfaces, especially spice bottles, is important to remove bacteria; Propyzamide weed killer interferes with anti-inflammatory regulation in the gut

Daniel Kahneman, a Nobel Prize-winning psychologist and renowned quantitative analyst, talks about how he applies the principles of behavioural science to analyze news and markets.

Dr. Lauren Kim interviews Dr. Yoon Hae Ahn and Dr. Hye-Ryun Kang to discuss "Allergic-like hypersensitivity reactions to Gadolinium-based contrast agents: An 8-year cohort study of 154 539 patients" Allergic-like Hypersensitivity Reactions to Gadolinium-based Contrast Agents: An 8-year Cohort Study of 154 539 Patients. Ahn and Kang et al. Radiology 2022; 303:329–336. 

Terence Kooyker, founder and CEO of the commodity hedge fund Valent Asset Management, rejoins the Essential Podcast to talk about the market and uses for the elements of the energy transition. In this episode, we return to the lanthanides to cover gadolinium, lucky element #64 on the Periodic Table.

This episode represents the final part of a series of conversations regarding the safety of gadolinium based contrast agents. Here we discuss who is most at risk for retaining gadolinium and how we can effectively get it out of the body using chelation therapy. I am joined by:Dr Richard Semelka - Dr Richard Semelka is a leading expert in Radiology for body MRI and gadolinium toxicity.He has written over 370 peer-reviewed papers and 16 text-books. and is the first doctor to publish on the entity of gadolinium deposition disease.Dr semelka offers clinical medical consultations for individuals experiencing gadolinium toxicity and in this discussion we will be observing practically how this is treated in the clinic.Kate Skardon - A patient advocate, continuing chelation therapy to remove gadolinium from the body following devastating consequences. Her story can be found here:   https://www.youtube.com/watch?v=4aozx...https://www.youtube.com/watch?v=1RvHA...Debbie Lambert- A patient advocate who seeks to raise awareness about Gadolinium Deposition Disease through various mediums, including the links below:https://m.facebook.com/pg/livingwithg...https://twitter.com/lambertdebbShow notes:HOPO Therapeutics- oral chelationhttp://www.hopotx.com/science/SAGE- Symptoms Associated with Gadolinium Exposurehttps://pubs.rsna.org/doi/abs/10.1148/radiol.2021211349

Gadolinium ist ein Kontrastmittel das bei der Anwendung eines MRT häufig eingesetzt wird. Obwohl häufig behauptet wird, dass Gadolinium binnen kürzester Zeit aus dem Körper ausgeschieden wird, kommt es in einigen Fällen zu einer chronischen Belastung. Die Folgen können chronische Müdigkeit, Schwindel, Sehstörungen, Herzrhythmusstörungen usw. sein. Dabei ist Gadolinium als Kontrastmittel oftmals gar nicht notwendig. Selbst das MRT muss nicht immer das Mittel der Wahl sein, sondern kann oftmals durch eine sanftere Therapie ersetzt werden. Du erfährst in diesem Interview, wie man sich auf eine Gadolinium-Belastung testen kann und wie es wieder ausgeleitet werden kann.   >>Hier geht's zu den Shownotes hier klicken hier klicken

Dr. Wagner is a clinical nephrologist. He is the Director of the Kidney Institute of New Mexico as well as being the acting Associate Chief of Research and Renal Section Chief for the VA in Albuquerque. This is the second time Dr. Wagner has been on the podcast with his research team. In this episode we re-examine the mechanisms behind gadolinium retention and receive updates on new discoveries.To fund Dr. Wagner's work you can donate to the Kidney Institute of New Mexico athttps://www.unmfund.org/fund/unm-kidney-institute-of-new-mexico/Links:Reveal Pharmaceuticals, Gadolinium-free MRI contrast agents products.http://www.revealpharma.comThe FDA adverse event reporting systemhttps://open.fda.gov/data/faers/Gadolinium-Based Contrast Agent Use, Their Safety, and Practice Evolutionhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8378745/

Gadolinium ist ein Kontrastmittel das bei der Anwendung eines MRT häufig eingesetzt wird. Obwohl häufig behauptet wird, dass Gadolinium binnen kürzester Zeit aus dem Körper ausgeschieden wird, kommt es in einigen Fällen zu einer chronischen Belastung. Die Folgen können chronische Müdigkeit, Schwindel, Sehstörungen, Herzrhythmusstörungen usw. sein. Dabei ist Gadolinium als Kontrastmittel oftmals gar nicht notwendig. Selbst das MRT muss nicht immer das Mittel der Wahl sein, sondern kann oftmals durch eine sanftere Therapie ersetzt werden. Du erfährst in diesem Interview, wie man sich auf eine Gadolinium-Belastung testen kann und wie es wieder ausgeleitet werden kann.   >>Hier geht's zu den Shownotes Hol dir jetzt die pure Energie! hier klicken hier klicken

Gadolinium ist ein Kontrastmittel das bei der Anwendung eines MRT häufig eingesetzt wird. Obwohl häufig behauptet wird, dass Gadolinium binnen kürzester Zeit aus dem Körper ausgeschieden wird, kommt es in einigen Fällen zu einer chronischen Belastung. Die Folgen können chronische Müdigkeit, Schwindel, Sehstörungen, Herzrhythmusstörungen usw. sein. Dabei ist Gadolinium als Kontrastmittel oftmals gar nicht notwendig. Selbst das MRT muss nicht immer das Mittel der Wahl sein, sondern kann oftmals durch eine sanftere Therapie ersetzt werden. Du erfährst in diesem Interview, wie man sich auf eine Gadolinium-Belastung testen kann und wie es wieder ausgeleitet werden kann.   >>Hier geht's zu den Shownotes Jetzt zuschlagen hier klicken hier klicken

Welcome to HerniaTalk LIVE, a Q&A hosted by Dr. Shirin Towfigh, hernia and laparoscopic surgery specialist who practices at the Beverly Hills Hernia Center. This is the only Q&A of its kind, aimed at educating and empowering patients about all things related to hernias and hernia-related complications. For a personal consultation with Dr. Towfigh: +1-310-358-5020, info@beverlyhillsherniacenter.com.This week, the topic of discussion was: Radiology Imaging MRI CT scan Ultrasound Hernias Mesh IV Contrast Gadolinium  Oral Contrast Adhesions PET scanIf you find this content informative, please LIKE, SHARE, and SUBSCRIBE to the HerniaTalk Live channel and visit us on www.HerniaTalk.com.Follow Dr. Towfigh on the following platforms:Youtube | Facebook | Instagram | Twitter

Full article: https://www.ajronline.org/doi/abs/10.2214/AJR.21.25924  Intracranial deposition of gadolinium after contrast-enhanced MRI is an emerging area of concern with much still to be learned. Kalen Riley, MD, MBA discusses a new article that proposes a dose-reduction strategy that takes advantage of relatively higher T1 relaxivity of one macrocyclic agent compared to another while still striving to maintain an adequate imaging examination.

Dr. Yavuz Nuri Ertaş lisans eğitimini Başkent Üniversitesi Biyomedikal Mühendisliği bölümünde tamamlaması akabinde Bilkent Üniversitesi'nde bulunan Ulusal Nanoteknoloji Araştırma Merkezinde, Malzeme Bilimi ve Nanoteknoloji programında yüksek lisansa başlamıştır. Burada mikro-nano fabrikasyon ve sensörler konularında araştırmalar yaptıktan sonra dünyanın en saygın okullarından Kaliforniya Üniversitesi'nde (UCLA) doktora eğitimine başlayan Ertaş, manyetik nanoparçacıkların üretimi ve MR kontrast ajanı olarak uygulamaları üzerine odaklanmıştır. Bu çalışmalar sırasında dünyada bir ilk olan Gadolinium nanoparçacıklarının yüksek saflıkta üretilebileceği bir nanofabrikasyon tekniği geliştirmiştir ve bu parçacıkların MR görüntülemede yüksek performans sergilediğini deneysel olarak göstermiştir. Doktora sonrası araştırmalarına yine UCLA'de devam edip üç boyutlu biyobaskı alanında yayınladığı son makalesi alanının en iyi dergilerinden Advanced Healthcare Materials’da kapak olarak yayınlanmıştır. TÜBİTAK 2232 Uluslararası Lider Araştırmacılar Programı kapsamında yurda kesin dönüş yapan Dr. Ertaş çalışmalarına Erciyes Üniversitesi Nanoteknoloji Araştırma Merkezi (ERNAM) ve Erciyes Üniversitesi Biyomedikal Mühendisliğinde devam etmektedir. #biyoprinting​ #3D​ Hazırlayanlar: Sunucu ► Melis Zenginler Konuk İletişim ► Yavuz Aydın Yayın Teknik/Reji ► Buse Kuloğlu Sosyal Medya/ İletişim ► Sosyal Medya Ekibi ––––––––––––––––––––––––––––– ► Gelecek Bilimde kanalımızda, bilimin her alanından özgün canlı yayınlar bulabilirsiniz. Fizikten biyolojiye, yapay zekadan psikolojiye, müzik analizinden astronomiye, satrançtan teknoloji haberlerine kadar birçok içeriği her gün kaçırmamak için kanalımıza abone olun! ► https://youtube.com/gelecekbilimde?su...​ ► Bize destek olmak için: https://www.youtube.com/gelecekbilimd...​ ► Yayınlarımızı izlemek için: YouTube Kanalı ► https://youtube.com/gelecekbilimde​ Twitch Kanalı ► https://twitch.tv/gelecekbilimde​ Podcast ► https://podcast.gelecekbilimde.net​ ► Bizi takip edin! Twitter ► https://twitter.com/gelecekbilimde​ Instagram ► https://instagram.com/gelecekbilimde​ ► Diğer Bağlantılarımız: Gönüllü Olmak İçin ► https://birlikte.gelecekbilimde.net​ Kaynaklar ► https://bit.ly/gb-kaynak​ İngilizce Kelimeler ► https://quizlet.com/Gelecek_Bilimde​ Discord ► https://discord.gelecekbilimde.net​ Kitaplık ► https://goodreads.com/gelecekbilimde​ Gelecek Bilimde canlı yayınlarında konuklarımızın sözlerinden sadece kendileri sorumludur. Gelecek Bilimde ve gönüllüleri hiçbir şekilde sorumlu tutulamaz.

In this episode we continue our discussion of Gadolinium-based contrast agents (GBCA) from our introduction in Ep 27. Building on previous discussions of MRI safety (Ep9 & 11) and Contrast and Adverse Reactions from Ep 5 & 6, this episode will review specific considerations of gadolinium use in pregnancy and breast feeding. We also explore the non-acute adverse reactions of NSF and GDD. This is part two of the two-part series on the basics of GBCA. Host: Hao Lo, MD, MBA. Associate Professor of Radiology, Division of Emergency Radiology, UMMS Dept of Radiology. Guest: Christopher Cerniglia, DO, ME, FAOCR. Associate Professor of Radiology, Division of Musculoskeletal Imaging & Intervention, UMMS Dept of Radiology. Resources: • Gadolinium-Based Contrast Agent Accumulation and Toxicity: An Update. J. Ramalho, R.C. Semelka, M. Ramalho, R.H. Nunes, M. AlObaidy, and M. Castillo.AJNR Am J Neuroradiol 37:1192–98. dx.doi.org/10.3174/ajnr.A4615 • Gadolinium Deposition Disease: A New Risk Management Threat. H. Benjamin Harvey, Vrushab Gowda, Glen Cheng. J Am Coll Radiol 2020;17:546-550. doi.org/10.1016/j.jacr.2019.11.009. creativecommons.org/licenses/by-nc-nd/4.0/ • ABR Noninterpretative Skills Guide 2020. www.theabr.org/wpcontent/uploads/2020/02/NIS-Study-Guide-2020.pdf

Let's gear up for the new year by making a decision to make positive changes next year. Be sure and write them down and focus on them often. Medical tests and procedures are often times necessary. However, it is still imperative to do your own research and consider the risks. MRI contrast-one type known as Gadolinium-can have serious side effects. Proceed with caution and wisdom.

Andrew Scarborough has a masters in nutritional therapy and a degree in human medical science. He's currently doing a postgraduate certification in clinical bioninformatics. He was diagnosed in 2013 with an incurable malignant brain tumour after having a brain haemorrhage on a train. We talk about: 8 years with a highly malignant brain tumour The public discussion of cancer therapies Interpreting cancer therapy studies Spontaneous remission Chemical & viral cancer triggers Genetic & environmental protection from cancer Andrew's e-book on the concerns around Gadolinium based contrast agents used in MRI scans Awareness of the problem within the industry New BHB coming soon from KetoSwiss Benefits of taking ketones Andrew can be found at: Twitter - https://twitter.com/ascarbs His podcast - https://podcasts.apple.com/us/podcast/the-human-guinea-pig-project/id1488201848 Ally can be found at: Twitter - https://twitter.com/paleocanteen Twitter - https://twitter.com/paleoally Instagram - https://www.instagram.com/paleocanteen YouTube - https://www.youtube.com/c/AllyHouston

Dr. Wagner is a clinical nephrologist. He is the Director of the Kidney Institute of New Mexico as well as being the acting Associate Chief of Research and Renal Section Chief for the VA in Albuquerque. In this episode we discuss recent evidence urging caution over the use of gadolinium based contrast agents.To fund Dr. Wagner's work you can donate to the Kidney Institute of New Mexico athttps://www.unmfund.org/fund/unm-kidn...Links:Reveal Pharmaceuticals, Gadolinium-free MRI contrast agents products.http://www.revealpharma.comPeter Caravan PhD. Director, Institute for Innovation in Imaging Massachusetts and Associate Professor of Radiology at Harvard Medical School.Twitter- @PeterCaravanThe FDA adverse event reporting systemhttps://open.fda.gov/data/faers/Gadolinium-based contrast agents: why nephrologists need to be concernedhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6416778/

This is one of the few places you will be able to find important information on risks of MRI dye (containing the toxic chemical gadolinium). Since I began reporting on this topic on Full Measure, many of these dyes have been banned in Europe and Japan. However, the FDA in the U.S. decided to keep them on the market and, instead, issued new warnings. However, the new warnings are very difficult to find. Investigative producer David Bernknopf joins me for this podcast. Share with your friends and family who might be interested in MRI dye safety. Read the text of the Full Measure story and watch the video investigation here. --- Send in a voice message: https://podcasters.spotify.com/pod/show/sharylattkissonpodcast/message

Listen to an audio podcast of the December 19, 2017 FDA Drug Safety Communication "FDA warns that gadolinium-based contrast agents (GBCAs) are retained in the body; requires new class warnings". This is an update to the FDA Drug Safety Communication: FDA identifies no harmful effects to date with br

Listen to an audio podcast of the May 22, 2017 FDA Drug Safety Communication. FDA announced that to date a review has not identified adverse health effects from gadolinium retained in the brain after the use of gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging (MRI); review to